X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.biopharmadive.com/news/astrazeneca-first-quarter-revenue-beat-cancer-drugs/714311/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-imfinzi-shows-promise-treating-aggressive-lung-cancer-2024-04-05/
https://www.biospace.com/article/astrazeneca-shows-lynparza-combo-could-address-unmet-endometrial-cancer-need/
https://www.globenewswire.com//news-release/2024/02/14/2829105/29489/en/AIM-ImmunoTech-Announces-First-Subject-Dosed-in-the-Netherlands-for-Phase-1b-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-T.html
https://www.globenewswire.com//news-release/2024/01/22/2813072/29489/en/AIM-ImmunoTech-Announces-that-the-First-Subject-is-Enrolled-in-the-Phase-1b-2-Study-Evaluating-Ampligen-in-Combination-with-AstraZeneca-s-Imfinzi-for-the-Treatment-of-Late-Stage-Pa.html
https://endpts.com/astrazenecas-imfinzi-combo-extends-pfs-in-liver-cancer-novartis-shares-new-details-about-lutatheras-phiii/
https://www.globenewswire.com//news-release/2024/01/10/2807133/29489/en/AIM-ImmunoTech-Announces-Open-Enrollment-for-Phase-1b-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-Treatment-of-Pancreatic-.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069
https://www.prnewswire.com/news-releases/biocity-announces-the-first-patient-dosed-with-its-anti-tim-3-mab-bc3402-in-combination-with-imfinzi-for-the-treatment-of-advanced-hepatocellular-carcinoma-in-a-phase-ibii-trial-302020549.html
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-imfinzi-plus-chemoradiotherapy-fail-main-goal-late-stage-trial-2023-11-14/
https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-approved-in-china-as-first-immunotherapy-regimen-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer.html
https://www.globenewswire.com//news-release/2023/10/23/2764565/0/en/Theriva-Biologics-Presents-Survival-Outcomes-Data-from-Phase-1-Study-Evaluating-VCN-01-in-Combination-with-Durvalumab-in-Patients-with-Recurrent-Metastatic-Squamous-Cell-Carcinoma-.html
https://www.onclive.com/view/perioperative-durvalumab-plus-soc-shows-promising-efs-results-in-muscle-invasive-urothelial-carcinoma
https://www.clinicaltrialsarena.com/news/astrazeneca-positive-endometrial-cancer-therapy/
https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-lynparza-prolonged-pfs-in-endometrial-cancer.html
https://news.cision.com/astrazeneca/r/imfinzi-plus-lynparza-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-adv,c3775242
https://www.fiercepharma.com/pharma/bristol-myers-squibb-accuses-astrazenecas-imfinzi-stepping-fellow-checkpoint-inhibitor
https://www.fiercepharma.com/pharma/astrazeneca-face-tough-fda-scrutiny-imfinzi-lynparza-ovarian-cancer-analyst
https://www.nasdaq.com/articles/astrazeneca-says-cancer-drug-imfinzi-improves-survival-rates-in-late-stage-trial
https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-gets-cdsco-nod-for-drug-to-treat-biliary-tract-cancer/articleshow/98004350.cms
https://www.fiercepharma.com/pharma/mercks-keytruda-takes-another-hit-prostate-cancer-rains-astrazenecas-parade
https://www.fiercepharma.com/pharma/bristol-myers-doubles-down-immuno-oncology-patent-fight-az-time-targeting-imjudo
https://www.pharmaceutical-technology.com/news/japan-astrazeneca-liver-lung-cancers/
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-eu-for-biliary-tract-cancer.html
https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-imfinzi-pearl-trial.html
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-recommended-for-approvals-in-eu.html
https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-imfinzi-pearl-trial.html
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer.html
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069
https://www.globenewswire.com/news-release/2022/10/24/2539914/0/en/Theriva-Biologics-Announces-Presentation-at-the-14th-International-Oncolytic-Virotherapy-IVOC-Conference-Describing-Phase-1-Investigator-sponsored-Study-Evaluating-VCN-01-in-Combin.html
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer.html
Market Place
Share 
